Regado Biosciences Raises $23 Million

Regado Biosciences Inc., a Durham, N.C.-based drug company focused on antidote-controlled antithrombotics, has raised $23 million in Series C funding. Caxton Advantage Life Sciences Fund was joined by return backers Domain Associates, Quaker BioVentures and the Aurora Funds. The company previously had raised around $21 million since its 2001 inception.